Objective: To follow up the effect of continuous levodopa-carbidopa intestinal gel infusion (LCIG) on motor and non-motor symptoms in advanced Parkinson’s disease (aPD).

Background: Non-motor symptoms have a major effect on the quality of life in PD patients. The long term effect of the LCIG treatment on non-motor symptoms in aPD patients is less known

Methods: 13 consecutive aPD patients whom LCIG treatment was introduced were recruited in this observational prospective pilot study. Before insertion of percutaneous enteroendoscopic gastrostomy (PEG baseline) patients underwent the following assessments of motor and non-motor symptoms: MMSE, MoCA, PDQ39, BDI, HAS, SCOPA-PC, PDSS2. The same evaluation was performed 6 months, 1 year and 2 years after initiation of LCIG treatment. Student T-test was performed to compare the baseline with the follow-up evaluations.

Results: The average age of aPD patients at baseline was 72,0 +/- 6,5 years, 7 were male. PD duration: 15,0 +/-4,8 years, MMSE score: 26,1 +/-4,0 MoCa: 22,0 +/-4,8, PDQ39: 57,1 +/-23,0, BDI: 20,9 +/-17,6, HAS: 19,9 +/-8,7, SCOPA-PC: 2,2 +/-1,5, PDSS2: 24,0+/-5,5.

The follow up evaluations showed a stable motor and non-motor signs. No statistically significant changes were observed in the studied motor and non-motor symptoms in this 2 years follow-up study.

Conclusions: LCIG treatment of aPD patients is associated with stable non-motor symptoms status up to two years after the start of the treatment.

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/non-motor-symptoms-in-parkinsonss-disease-patients-treated-with-levodopa-carbidopa-intestinal-gel-infusion-the-follow-up-study/